A phase 3 (COSMIC-311), randomized, double-blind, placebo-controlled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy.
Publication/Presentation Date
5-2019
Volume
37
Issue
15
Published In/Presented At
DOI: 10.1200/JCO.2019.37.15_suppl.TPS6097
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS